Institutional Biosafety Committee (IBC)
eIBC software upgrade in June 2017
The eIBC system is getting a software upgrade. This upgrade will require the eIBC system to be offline from the afternoon of Thursday, June 1st, through Sunday, June 4th. Researchers with open actions and pending renewals will be contacted directly.
The protocol submission and review process remains unchanged. The impacts of this upgrade is that there is a new look and feel to the user interface –such as font, colors and layout.
The NIH Guidelines Involving Recombinant or Synthetic Nucleic Acid Molecules, defines these nucleic acid molecules as:
(i) molecules that (a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids;
(ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e. synthetic nucleic acids, or
(iii) molecules that result from the replication of those described in (i) or (ii) above.
Infectious Agents are generally defined as risk group 2 agents and above (agents that can cause disease in healthy adult humans).
Use of Biologically Derived Toxins need only be reviewed by the IBC if the toxin is a select agent, or if the toxin is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight